A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck - NCT01059643-30060(Clinical Trial 665171)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Marietta |
|
State:
|
|
GA |
| Zip Code: |
|
30060 |
| Conditions: |
|
Ovarian Cancer - Non Small Cell Lung Cancer - Prostate Cancer - Colorectal Cancer - Gastric Cancer - Esophageal Cancer - Cancer of Head and Neck |
| Purpose: |
|
The purpose of the study is to estimate the rate of response for patients with ovarian,
non-small cell lung, prostate, colorectal, gastroesophageal, and head and neck cancers who
are administered LY2523355.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Diagnosis of ovarian, non-small cell lung, prostate, colorectal, gastroesophageal
cancer, or squamous cell cancer of the head and neck
- Have measurable disease defined by Response Evaluation Criteria in Solid Tumors
(RECIST) 1.1 guidelines (except prostate cancer patients)
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Are willing to follow study procedures for the duration of the study
- Are willing to use an approved contraceptive method during treatment and for 3 months
after discontinuation of study treatment
Exclusion Criteria:
- Have a serious preexisting medical condition that would preclude participation in the
study
- Are pregnant or lactating
- Have received treatment within 28 days of first dose of LY2523355 with a drug that
has not received regulatory approval for any indication
- Have symptomatic, untreated, or uncontrolled central nervous system (CNS) metastases
- Have a second active primary malignancy or a history of a second malignancy requiring
cytotoxic therapy
- Have QTc interval greater than 470 msec or intraventricular conduction delay (IVCD)
with QRS greater than 120 msec on screening electrocardiogram (ECG)
- Have active symptomatic fungal, bacterial, and/or known viral infection including
active human immunodeficiency virus (HIV) or viral (A, B, C) hepatitis
- Patients with pneumonia, evidence of obstructive pneumonitis, other respiratory
infections, or infection from other sources are to be excluded |
|
|
|
| Study is available at: |
|
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Marietta, GA 30060
United States
Primary Contact:
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Phone: 1-317-615-4559 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 23, 2011 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|